Journal
BLOOD
Volume 116, Issue 24, Pages 5126-5129Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2010-06-290668
Keywords
-
Categories
Funding
- National Cancer Institute, National Institutes of Health [CA62242, CA93842, CA10080]
- Department of Health and Human Services
- Paul Calabresi K12 grant
Ask authors/readers for more resources
Immunoglobulin free light chains (FLCs) are the precursors of amyloid fibrils in primary amyloidosis (AL). We studied the relationship between FLC levels and clinical features in 730 patients with newly diagnosed AL. The plasma cell clone was lambda in 72% patients, and kappa in 28% patients. kappa-AL had more GI tract and liver involvement, where as renal involvement was more with lambda-AL. While the overall survival (OS) was similar for kappa and lambda-AL, the median OS for those without an identifiable serum heavy chain was significantly shorter (12.6 vs 29.9 months; P = .02). The OS was shorter among those with a higher dFLC (involved FLC-uninvolved FLC; kappa > 29.4 mg/ dL or lambda > 18.2 mg/dL using median for cutoff); 10.9 vs 37.1 months; P < .001. In multivariate analysis, dFLC was independent of other prognostic factors. The type of light chain impacts the spectrum of organ involvement and the FLC burden correlates with survival in AL. (Blood. 2010;116(24):5126-5129)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available